Home > Boards > Free Zone > Penny Fundamentals > Stock Room

$VDRM ViaDerma, Inc. Set to Launch Two New

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AskMuncher Member Profile
Followed By 398
Posts 17,487
Boards Moderated 1
Alias Born 06/07/18
160x600 placeholder
STOXX Europe 600 Index Ends 1.68% Higher at 467.31 -- Data Talk
The STOXX Europe 600 Index is up 7.72 points or 1.68% today to 467.31
FTSE 100 Index Ends 1.33% Higher at 7469.78 -- Data Talk
UBS Acquires Wealthfront in $1.4 Billion All-Cash Transaction
Teck Resources to Deploy Fleet of Caterpillar Zero-Emission Vehicles at Operations
Inventories of Ethanol Climb to Highest Since 2020
U.S. Oil Inventories Surprisingly Rise as Refinery Activity Slows
U.S. New Home Sales Increased Sharply in December to Nine-Month High
Titan Medical Receives Milestone Net Payment of $8.3M
GDP Seen +5.5% in 4Q -- Data Week Ahead
Top Company News of the Day
MamaMancini's Shares Up After Amazon Fresh Authorization
Brazil Current Account Deficit Narrowed in December to $5.9 Billion
Adidas to Hire More Than 2,800 New Employees This Year
Cortexyme Shares Slide Premarket as FDA Puts Hold on Atuzaginstat
Finland Sells EUR3 Billion in April 2043 Government Bond
Norfolk Southern Names Amy Miles Non-Executive Chairwoman
Kimberly-Clark Expects Growth in 2022 Despite Inflation, Supply-Chain Challenges
Abbott Sees 2022 Adjusted Earnings of at Least $4.70/Share
Abbott Labs Posts 4Q Sales Growth, Beats Expectations
Mattel Shares Rally Premarket on Recapture of Disney Business
Kimberly-Clark 4Q Profit Falls Amid Higher Costs
Kimberly-Clark Raises Quarterly Dividend by 1.8% to $1.16
ADP Raises Fiscal Year 2022 Guidance
Immunocore Gets FDA OK of Kimmtrak in Uveal Melanoma
ADP Posts Higher 2Q Sales, Profit
FTSE Gains, Renew Holdings Could Capitalize on GBP640 Billion Infrastructure Spend
Clean Energy Fuels to Construct Methane Capture Digester in Idaho
TE Connectivity Expects 2Q Growth Amid Strong Demand
AskMuncher   Tuesday, 10/05/21 03:44:14 AM
Re: None
Post # of 12049 
$VDRM ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra
Press Release | 10/04/2021
LOS ANGELES, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) is pleased to announce they are launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra.

The original Vitastem is an FDA-registered drug and one of the world’s strongest topical antibiotics. Its active ingredient is tetracycline. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). The new formula is clear and colorless compared to the brownish color of the original, so it will not stain the skin, fingernails, toenails, or anywhere else it is applied.

The Company is also unveiling its new Vitastem Ultra. The active ingredient in Vitastem Ultra is bacitracin. This provides an alternative for people who are allergic to tetracycline, as well as a way to treat tetracycline resistant bacteria. Additionally, Vitastem Ultra will open new doors overseas in many markets that prefer tetracycline alternatives. Like the new and improved Vitastem, Vitastem Ultra is colorless and non-staining. Batches of the new products are currently being produced and are expected to be available to consumers on Amazon, Vitastem.net and other ViaDerma resellers by mid-October. The old version will no longer be sold, and all new and future purchase orders will be filled with the new products.

“I am very excited to get these two new products on the market,” said Dr. Chris Otiko, ViaDerma President and CEO. “Vitastem has always received great reviews, but the one suggestion that came up from time to time was if we can make it non-staining. I am happy to announce we have addressed that issue.”

Dr. Otiko also said, “Our new Ultra product is a great alternative for people who cannot use tetracycline. Ultra will provide the same great results as the original.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com

Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-734-6111
Follow us on Twitter: ViaDerma Official @viaderma
Like us on Facebook: ViaDerma-VDRM @viadermapharma

Hi my posts are for entertainment purposes only. Consult a professional. And if it lasts longer than 4 hours, call a physician with a good camera.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences